'How One Man Built the Largest "Invention Factory" in Human History'

In the mid-1970s, Robert Langer, working as a chemical engineer at Boston Children’s Hospital, proposed using polymer materials to deliver large molecules, such as proteins, into the body over extended periods. His initial grant proposals faced significant skepticism from the scientific community, which largely considered the controlled release of large molecules through polymers to be technically unfeasible.

Despite early rejections, Langer's research proved successful. He is now one of the most cited engineers in history, holding over 1,500 patents and co-founding over 40 companies, including Moderna. His work in controlled-release drug delivery systems established the foundational technology for the mRNA vaccines used during the COVID-19 pandemic.

Early Life and Education

Robert Langer was born in 1948 in Albany, New York. As a child, he developed a strong interest in chemistry, conducting experiments in a home laboratory. He pursued this interest academically, eventually earning a PhD in chemical engineering from MIT.

Following his graduation in 1974, Langer chose not to enter the petroleum industry, a common path for chemical engineers at the time. Instead, he joined the laboratory of Dr. Judah Folkman, a surgeon researching methods to inhibit tumor growth by restricting their blood supply (angiogenesis).

Developing Controlled-Release Polymers

Folkman required a method to deliver an angiogenesis inhibitor to a tumor continuously over several weeks. Langer addressed this engineering challenge by mixing the drug powder with a liquid polymer and freezing it. This process created a "tortuous path"-a complex network of microscopic pores. Rather than diffusing directly through the solid polymer, the large molecules slowly traveled through these pores, allowing for a controlled and predictable release rate.

While laboratory tests confirmed the viability of this approach, Langer's initial attempts to secure research funding were repeatedly rejected. Colleagues expressed doubt about the feasibility of polymer-based delivery for large molecules.

The Langer Lab and Commercialization

By the late 1980s, Langer’s polymer delivery systems had gained acceptance and were being applied in treatments for various conditions, including brain cancer and prostate cancer. He returned to MIT as a faculty member and established the Langer Lab, which has since trained over 1,000 researchers.

Langer actively encouraged the commercialization of laboratory discoveries to bridge the gap between academic research and clinical application. He supported his students in forming startups, securing venture capital, and navigating the patent process.

This infrastructure facilitated his later collaboration with Moderna, a startup exploring the use of mRNA for therapeutics. Langer contributed his expertise in delivery systems, aiding in the development of lipid nanoparticles designed to protect the fragile mRNA molecules and facilitate their entry into cells.

Future Research Directions

Robert Langer continues his research at MIT. His current projects include the development of orally administered systems capable of remaining in the stomach for extended periods to deliver medication for diseases like malaria and tuberculosis. His lab also researches tissue engineering, utilizing polymer scaffolds to support the growth of new biological tissues.